Techdow is among the first few Chinese pharmaceutical companies that have built their own sales teams overseas. Techdow's enoxaparin sodium injection is currently sold to over 40 countries and regions across the world and included by the national insurance programs of the top 13 EU countries, United Kingdom, and Switzerland, winning broad recognition for the product globally.
China
United States
United Kingdom
Switzerland
Poland
France
Germany
Italy
Spain
Czech Republic
Austria
Danmark
Croatia
Finland
Portugal
Slovenia
Sweden
Canada
Brazil
Columbia
Peru
Chile
Paraguay
Bolivia
Albania
Bosnia and Herzegovina
Kosovo
Ukraine
Malaysia
Philippines
Vietnam
Kazakhstan
Saudi Arabia
UAE
Jordan
Palestine
Iraq
Sri Lanka
Uzbekistan
Madagascar
Macedonia
.jpg)
Serbia
El Salvador
DC00A99B13B4401689D3FCEAA6FE3CD7.jpg)
Indonesia
Montenegro
Australia
Brunei
Ecuador
Techdow now operates in 7 countries across the globe
In 2005, Techdow's enoxaparin sodium injection (Prolongin®) became the first generic enoxaparin approved for China market by the National Medical Product Administration (NMPA, also formerly known as CFDA). In 2020, All SKUs of enoxaparin sodium injection (Prolongin®) marketed in China passed the Bioavailability Equivalence Evaluation of the Quality and Efficacy of Biosimilar, and became the first product that passed the evaluation in China at the time. In 2023, Techdow's enoxaparin sodium injection (Prolongin®) became the first enoxaparin product selected by the 8th Centralized National Procurement in China.
In 2016, Techdow's enoxaparin sodium injection (Inhixa/Neoparin) was approved in the EU as the company's first branded biosimilar in the region. Subsequently, Techdow built local sales teams for the 5 major European markets (Poland, Italy, United Kingdom, Germany, Spain) and commenced local production and distribution of the product in 18 countries including Austria, France, Finland, and the Czech Republic. As of June 2023, Techdow has cumulatively sold approximately 480 million vials of its enoxaparin sodium injection in the European market.
As a drug and API supplier to Sandoz, a company granted marketing authorization for enoxaparin sodium preparations, Techdow officially began supplying enoxaparin sodium preparations to the U.S. market in 2020.In 2021, Techdow started building its own local sales team in the U.S. and subsequently began selling its heparin sodium injections in the country in 2022. In 2023, Techdow's enoxaparin sodium injection product (product name: Enoxaparin Sodium Injection, USP) was approved by the U.S. Food and Drug Administration (FDA) and subsequently launched in the U.S. market.
In 2019, Techdow's enoxaparin sodium injections began entering non-U.S./European markets, and have thus far obtained marketing authorizations in 37 countries and regions including Australia, Canada, Brazil, Saudi Arabia, and Malaysia etc. Techdow's business now covers North America, Central and South America, the Middle East, Southeast Asia, and the Balkans, winning broad recognition from medical experts and physicians in those markets.
